Arimidex, Buy Arimidex, Arimidex Side Effects
images
Home       |      Services       |      Resources       |      Site Map       |      Contact Us
                MENU
icon Arimidex side effects
icon Arimidex for man
icon Arimidex anastrozole side effects
icon Arimidex tamoxifen
icon Generic arimidex
icon Arimidex atac tamoxifen
icon Arimidex medication
icon Arimidex joint pain
icon Breast cancer arimidex
icon

Arimidex and weight gain

icon Arimidex hair loss
icon Arimidex drug effects more side
icon Anastrozole arimidex man
icon Arimidex bone pain
icon Arimidex drug prescribed
   
  Featured Links
 
icon Anabolic Steroids
icon Buy Steroids
icon Buy Steroids
icon Steroid Abuse
   
   
Arimidex atac tamoxifen:
Arimidex is an aromatase inhibitor (sometimes called an AI). It is usually provided in 1MG tabs or in liquid form. The drug works in a non-steroid form by inhibiting the aromatase enzyme which convertstestosterone and other androgens into estrogen. This means that there is less estrogen tocause female pattern fat deposits, gyno, and water retention. In medicine, Arimidex isutilized to treat prostate cancer. In sports chemistry, the drug has been employed as ameans of preventing excessive estrogenic side effects during AAS use and to aid increating a harder appearing musculature for competitive bodybuilders. Unlike Nolvadex,which simply block estrogen receptor-sites, this drug prevents or reduces estrogenproduction. Though some estrogen presence is noted as necessary for AAS to reach fulleffectiveness, too much can cause a layer of fat, water retention, and breast tissue growthpotentially with tumors called gynecomastia or bitch tits. Arimidex has a 75-85%aromatization inhibition rate.

Males who experienced excessive aromatization of AAS or who were extremelyestrogen sensitive usually utilized a dosage of 0.5-3.0 mg daily. In fact, most realizedexcellent estrogen control with only 0.5mg/d (mg daily). Women usually showedexcellent lean appearances (even in their legs) with 0.5-1.0 mg daily. Arimidex has a veryshort active-life so 0.5 mg dosages were often taken 2-6 times daily at equal intervals.Stacking 10-30 mg of Nolvadex with 1.0 mg of Arimidex has resulted in a near "0"estrogen activity situation regardless of the AAS protocol utilized. Directly following anAAS cycle, estrogen control has also become a problem (during periods intended for reestablishingHPTA function). In this case, the dosage was reduced from a higher startingdosage to a low dosage that was continued for 7-14 days after AAS discontinuance. Thisprotocol was considered necessary to assure clearing of AAS induced estrogen build-up.

Reported Characteristics:
Active-Life: 4-6 hours Drug Class: Aromatase inhibitor (Oral) Average Reported Dosage: 0.5-3.0 mg daily Acne: No Water Retention: None Liver Toxic: Yes dosage dependent Decreases HPTA function: Increases it.

TRADE NAMES:
ARIMIDEX .25 MG TABS (International Pharmaceuticals) ARIMIDEX 1mg
Orbotech downgraded to "hold"
NEW YORK, January 6 (newratings.com) - Analysts at Maxim Group downgrade Orbotech (ticker: ORBK) from "buy" to "hold." [more]


Western Union upgraded to "outperform"
NEW YORK, January 6 (newratings.com) - Analysts at Morgan Keegan upgrade Western Union (ticker: WU) from "market perform" to "outperform." [more]


Tree.com upgraded to "buy"
NEW YORK, January 6 (newratings.com) - Analysts at Stifel Nicolaus & Company upgrade Tree.com (ticker: TREE) from "hold" to "buy." The target price is set to $5.75. [more]


XTO Energy upgraded to "buy"
NEW YORK, January 6 (newratings.com) - Analysts at KeyBanc Capital Markets upgrade XTO Energy (ticker: XTO) from "hold" to "buy." [more]


SW Energy upgraded to "buy"
NEW YORK, January 6 (newratings.com) - Analysts at KeyBanc Capital Markets upgrade SW Energy (ticker: SWN) from "hold" to "buy." [more]


YRC Worldwide upgraded to "market perform"
NEW YORK, January 6 (newratings.com) - Analysts at Wachovia Securities upgrade YRC Worldwide (ticker: YRCW) from "underperform" to "market perform." [more]


Blockbuster initiated with "buy"
NEW YORK, January 6 (newratings.com) - Analysts at Janney Montgomery Scott initiate coverage of Blockbuster Inc (ticker: BBI) with a "buy" rating. [more]


Netflix initiated with "neutral"
NEW YORK, January 6 (newratings.com) - Analysts at Janney Montgomery Scott initiate coverage of Netflix Inc (ticker: NFLX) with a "neutral" rating. [more]


BMC Software upgraded to "buy"
NEW YORK, January 6 (newratings.com) - Analysts at UBS upgrade BMC Software (ticker: BMC) from "neutral" to "buy." [more]


Lululemon Athletica initiated with "underperform"
NEW YORK, January 6 (newratings.com) - Analysts at Cowen & Co initiate coverage of Lululemon Athletica Inc (ticker: LULU) with an "underperform" rating. [more]


Apple upgraded to "outperform"
NEW YORK, January 6 (newratings.com) - Analysts at Oppenheimer & Co upgrade Apple (ticker: AAPL) from "perform" to "outperform." The target price is set to $135. [more]


Google upgraded to "neutral"
NEW YORK, January 6 (newratings.com) - Analysts at Merriman Curhan Ford upgrade Google (ticker: GOOG) from "sell" to "neutral." [more]


Intercontinental Exchange downgraded to "neutral"
NEW YORK, January 6 (newratings.com) - Analysts at American Technology Research downgrade Intercontinental Exchange (ticker: ICE) from "buy" to "neutral." [more]


Garmin downgraded to "neutral"
NEW YORK, January 6 (newratings.com) - Analysts at Dougherty & Company downgrade Garmin (ticker: GRMN) from "buy" to "neutral." The target price has been reduced from $26 to $22. [more]


Stryker downgraded to "neutral"
NEW YORK, January 6 (newratings.com) - Analysts at Cowen & Co downgrade Stryker (ticker: SYK) from "outperform" to "neutral." [more]


Knot downgraded to "neutral"
NEW YORK, January 6 (newratings.com) - Analysts at Susquehanna Financial  downgrade The Knot (ticker: KNOT) from "positvie" to "neutral." [more]


UTi Worldwide initiated with "hold"
NEW YORK, January 6 (newratings.com) - Analysts at Stifel Nicolaus & Company initiate coverage of UTi Worldwide Inc (ticker: UTIW) with a "hold" rating. [more]


Cyber Source downgraded to "hold"
NEW YORK, January 6 (newratings.com) - Analysts at Wedbush Morgan downgrade Cyber Source (ticker: CYBS) from "buy" to "hold." The target price has been reduced from $15 to $13. [more]


Expeditors International of Washington initiated with "hold"
NEW YORK, January 6 (newratings.com) - Analysts at Stifel Nicolaus & Company initiate coverage of Expeditors International of Washington Inc (ticker: EXPD) with a "hold" rating. [more]


Genzyme initiated with "buy"
NEW YORK, January 6 (newratings.com) - Analysts at Morgan Joseph initiate coverage of Genzyme Corporation (ticker: GENZ) with a "buy" rating. The target price is set to $81. [more]


NET Servicos de Comunicacao initiated with "buy"
NEW YORK, January 6 (newratings.com) - Analysts at Citigroup initiate coverage of NET Servicos de Comunicacao SA (ticker: NETC) with a "buy" rating. [more]


Endo Pharma downgraded to "neutral"
NEW YORK, January 6 (newratings.com) - Analysts at Cowen & Co downgrade Endo Pharma (ticker: ENDP) from "outperform" to "neutral." [more]


Telefonos de Mexico initiated with "sell"
NEW YORK, January 6 (newratings.com) - Analysts at Citigroup initiate coverage of Telefonos de Mexico SAB de CV (ticker: TMX) with a "sell" rating. [more]


Telmex Internacional initiated with "sell"
NEW YORK, January 6 (newratings.com) - Analysts at Citigroup initiate coverage of Telmex Internacional (ticker: TII) with a "sell" rating. [more]


Endo Pharma downgraded to "average"
NEW YORK, January 6 (newratings.com) - Analysts at Caris & Company downgrade Endo Pharma (ticker: ENDP) from "above average" to "average." The target price has been reduced from $28 to $21. [more]


Telecomunicacoes de Sao Paulo initiated with "sell"
NEW YORK, January 6 (newratings.com) - Analysts at Citigroup initiate coverage of Telecomunicacoes de Sao Paulo SA Telesp (ticker: TSP) with a "sell" rating. [more]


Gallagher initiated with "neutral"
NEW YORK, January 6 (newratings.com) - Analysts at Piper Jaffray initiate coverage of Gallagher (Arthur J) & Co (ticker: AJG) with a "neutral" rating. [more]


MoneyGram downgraded to "market perform"
NEW YORK, January 6 (newratings.com) - Analysts at Morgan Keegan downgrade MoneyGram (ticker: MGI) from "outperform" to "market perform." [more]


Itron initiated with "buy"
NEW YORK, January 6 (newratings.com) - Analysts at Merriman Curhan Ford initiate coverage of Itron Inc (ticker: ITRI) with a "buy" rating. [more]


AthenaHealth downgraded to "hold"
NEW YORK, January 6 (newratings.com) - Analysts at Stifel Nicolaus & Company downgrade AthenaHealth (ticker: ATHN) from "buy" to "hold." [more]


 
Home    |    Services   |    Resources  |    Site Map  |    Contact Us
Copy rights reserved by iarimidex.com